Inside Nigeria’s Online Weight-Loss Drug Market: Prescription Medicines, Fake Claims & Regulatory Gaps
By JOANNA ILUSANMI
THE growing popularity of injectable weight-loss medicines in Nigeria is creating a new digital marketplace where prescription drugs are being offered without prescriptions, safety risks are downplayed and experimental medicines are marketed to consumers.
An investigation found that social media platforms and a network of largely anonymous websites are helping vendors reach Nigerians seeking rapid weight loss.
The investigation also uncovered websites using apparent customer testimonials that could not be independently verified, while some platforms promoted retatrutide, an experimental medicine still undergoing clinical trials.
The findings raise questions about the ability of Nigeria’s pharmaceutical regulatory system to monitor an expanding online market in medicines that require professional supervision.
A celebrity post opens a window into the market
The investigation began after media personality Toke Makinwa disclosed on Snapchat on May 6 that she had used Mounjaro before returning to the gym following childbirth.
Her post generated discussions about the drug, its effectiveness and its cost. Social media users began asking where they could obtain it.
Vendors quickly entered the conversation.
Responses to Instagram posts amplifying Makinwa’s disclosure included direct advertisements for Mounjaro and offers to sell the injection. What appeared initially to be routine online marketing became an entry point into a wider examination of how prescription weight-loss medicines are being sold in Nigeria.
The investigation found vendors offering Mounjaro without requesting prescriptions or evidence of medical supervision. Some also assured prospective customers that the injections had no side effects.
Those claims conflict with manufacturers’ safety information.
Prescription medicines sold through informal channels
Mounjaro contains tirzepatide and is manufactured by Eli Lilly. It is a prescription medicine approved for blood-sugar control in adults with type 2 diabetes. The company also markets tirzepatide under the Zepbound brand for chronic weight management in eligible adults.
Ozempic, manufactured by Novo Nordisk, contains semaglutide and is also a prescription medicine originally developed for adults with type 2 diabetes.
Both medicines belong to a class known as GLP-1 receptor agonists. They influence appetite and blood-sugar regulation and have become increasingly prominent in weight-management treatment.
But their growing popularity has also created a commercial opportunity for vendors operating outside conventional medical channels.
During the investigation, one Instagram-based vendor claimed to sell Mounjaro and described the product as highly effective. When asked about possible side effects, the vendor reportedly said there were none.
Another vendor, operating under the name Abuja Massues, advertised three categories of weight-loss injections at prices ranging from ₦100,000 to ₦250,000 per shot.
A third vendor similarly dismissed safety concerns and repeatedly told an undercover prospective customer that there were no side effects.
Medical risks hidden behind marketing claims
The claims made by the vendors are contradicted by medical evidence.
Eli Lilly’s safety information identifies nausea, diarrhoea, vomiting, constipation, indigestion and abdominal pain among common side effects associated with Mounjaro. More serious risks can include pancreatitis, severe allergic reactions, gallbladder problems and kidney injury associated with dehydration.
Endocrinologist Oladapo Ashiru said people should not begin GLP-1 treatment without proper clinical assessment and monitoring.
He said patients should undergo baseline assessments, including blood-sugar testing and other appropriate medical investigations, before treatment begins.
Ashiru also recounted treating a Nigerian patient who developed severe hypovolaemia after unsupervised use of weight-loss injections.
The medical concern therefore extends beyond whether consumers obtain genuine medicines. It also involves whether they receive appropriate diagnosis, dosage guidance, monitoring and management of adverse reactions.
The experimental drug being sold online
The investigation uncovered another layer of concern.
Some vendors were marketing retatrutide, an experimental medicine developed by Eli Lilly.
Unlike approved prescription medicines, retatrutide remains under clinical investigation and is not available for routine public use. At the time of the investigation, it was in Phase III clinical trials.
Yet websites targeting Nigerian consumers advertised the product for sale.
One network of websites listed retatrutide in different quantities and attached prices running into hundreds of thousands of naira. The platforms included purchasing functions that allowed visitors to add products to a virtual shopping cart.
Some pages described the products as being for “research use only”.
The investigation found that such disclaimers did not prevent the websites from facilitating commercial transactions with individuals.
A web of apparently connected platforms
The investigation identified five websites that appeared closely connected through their design, content and marketing strategies.
They included mounjaronigeria.com, slimnaija.com, naijatrim.com, naijapeptides.com and mounjaro.ng.
Several of the websites used similar language and promoted comparable products. Their domain-registration dates were also clustered within a relatively short period in January and February 2026.
The domains were registered through Cloudflare, with registrant information shielded by privacy protection.
Privacy protection by itself does not establish common ownership. However, the combination of similar designs, overlapping content, similar product offerings and interconnected links raised questions about whether the platforms were operated independently.
The investigation pursued those questions further.
Alleged testimonials under scrutiny
Two of the websites displayed testimonials attributed to supposed customers who claimed to have lost significant amounts of weight.
The photographs accompanying the testimonials were subjected to reverse-image searches.
The images were traced to Unsplash, a stock-photo platform.
That finding did not establish that the individuals pictured had used the advertised products. Instead, it raised serious doubts about the authenticity of the testimonials being presented to prospective customers.
For a consumer considering an expensive medical product, such testimonials can create an impression of effectiveness that may not be supported by independently verified evidence.
Following the money
The investigation also examined the commercial links connecting the websites.
WhatsApp links on two of the platforms redirected users to the same United States telephone number.
When contacted as a prospective customer, the operator provided product information, prices, dosage options and nationwide delivery details.
No prescription or medical history was requested.
Payment information provided by the operator pointed to an account in the name of Velorix Nigeria Ltd.
Corporate Affairs Commission records showed that the company was incorporated in February 2026, shortly after the relevant websites had been registered.
The company’s registered director and shareholder was identified as Samson Olufuwa.
The timing and payment trail provided an important lead in understanding the commercial structure behind the online marketplace.
However, the evidence did not by itself establish that the company owned or operated all the websites.
Company denies operating the websites
After being contacted for a response, Olufuwa’s lawyer, Chinualum Mmuozoba of Acreage Associates, denied that Velorix Nigeria Ltd owned or operated the websites identified in the investigation.
The lawyer said the company had only provided technology-related services to a third-party client.
He added that after the company became aware of the findings, it suspended the services it had been providing, including the technical payment facility.
The websites became inaccessible shortly after the company was contacted.
Archived copies of the platforms had, however, been preserved before the request for comment.
What Nigerian law requires
The investigation also examined the legal framework governing prescription medicines and pharmaceutical advertising in Nigeria.
Human rights lawyer and health-law advocate Bernard Okpi said Nigerian regulations restrict the advertising of prescription medicines to the general public through online platforms and other mass communication channels.
He cited the NAFDAC Drug and Related Products Advertisement Regulations 2021 and the Food, Drugs and Related Products (Registration, etc.) Act.
According to him, medicines intended for commercial distribution must comply with registration requirements, while the advertisement, sale or distribution of unregistered pharmaceutical products can attract regulatory and legal consequences.
He also argued that disclaimers such as “educational purposes only” or “research use only” would not automatically protect a platform if its actual conduct involves facilitating the supply of products for human use.
NAFDAC’s response
NAFDAC was asked through a Freedom of Information request to clarify the registration status of Mounjaro, Ozempic and retatrutide.
In its response, the agency did not give a categorical answer on the registration status of the three products in the precise terms requested. It stated generally that medicines intended for commercial distribution in Nigeria are required to undergo registration before marketing.
The agency also noted that certain unregistered medicines may enter Nigeria through controlled access pathways under defined regulatory conditions.
However, it did not establish that the products identified during the investigation had entered the country through such pathways.
NAFDAC had previously issued public alerts concerning Ozempic, including warnings that it was not registered in Nigeria and that falsified versions were circulating.
The agency also said it was intensifying monitoring of online medicine sales and could take measures including investigation, seizure, sanctions, prosecution and public alerts where violations are established.
A regulatory challenge moving online
The investigation highlights a difficult problem for regulators.
Traditional pharmaceutical enforcement has largely focused on physical pharmacies, distributors, importers and markets. Digital commerce has created a more dispersed marketplace in which sellers can advertise through social media, communicate through encrypted or semi-private messaging platforms and arrange nationwide delivery without maintaining conventional storefronts.
The consumer may therefore encounter a prescription medicine in the same online environment used to purchase clothing, cosmetics or household products.
That blurring of boundaries creates risks.
The central issue is not merely the popularity of weight-loss injections. It is whether Nigerians can distinguish legitimate medical treatment from informal drug sales, misleading advertising and experimental products presented as established therapies.
The cost of an unregulated market
The demand for weight-loss injections is unlikely to disappear simply because regulators issue warnings.
As obesity and weight-management concerns grow, and as social media personalities and influencers increase public awareness of GLP-1 medicines, demand may continue expanding.
That makes effective regulation increasingly important.
Doctors need to be able to identify unsafe use. Regulators need effective systems for monitoring online vendors. Digital platforms may need stronger mechanisms for detecting illegal pharmaceutical advertising. Consumers also need accessible information about approved medicines, legitimate sources and potential risks.
The investigation ultimately reveals a market developing faster than conventional enforcement mechanisms can easily follow.
Behind the advertisements, attractive testimonials and promises of rapid weight loss is a more complicated reality: prescription medicines are being marketed in informal digital spaces, experimental compounds are being offered for sale, and consumers may be making medical decisions without the professional supervision that such treatments require.
For Nigeria, the challenge is therefore no longer confined to regulating what happens inside pharmacies.
It increasingly involves regulating what happens on screens.
